Literature DB >> 7821970

Protection against natural killer cells by interferon-gamma treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression.

M Nishimura1, S Mitsunaga, T Akaza, Y Mitomi, K Tadokoro, T Juji.   

Abstract

Prior study has revealed that the expression of certain major histocompatibility complex (MHC) class I molecules on the membranes of normal or transformed cells can prevent natural killer (NK)-cell-mediated killing. This has been explained by either (1) the target interference model, or (2) the effector inhibition model. In both cases, MHC class I molecules are concerned but the precise mechanisms are still unclear. The erythroleukaemia K562 cell is known as a NK-sensitive target. This sensitivity has been explained mostly as being due to lack of MHC class I antigens on the K562 membrane. However, several recent studies have indicated that the expression of MHC class I antigens on the cell does not solely explain the protection against NK cells. To elucidate the mechanism of NK-cell-mediated killing, we investigated the killing profiles of the K562 cells by NK cells. Previous studies indicated that the NK-sensitive K562 cells can express some MHC class I antigens on their surface, and become protective against NK-cell killing after treatment with human interferon-gamma (hIFN-gamma). In the present study, we show that this resistance is not rendered by MHC class I expression, because addition of anti-MHC class I monoclonal antibodies (mAb) in the killing assay of hIFN-gamma-treated K562 cells, which express MHC class I antigens as the target, did not restore the sensitivity to NK cells. Moreover, we show that spontaneously occurring K562 clones which could not express MHC class I antigens even after hIFN-gamma treatment, could be protected after treatment with the cytokine. Taken together, these results strongly suggest that the susceptibility of K562 cells to NK cell killing is due to some elements distinct from those related to MHC class I antigens.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7821970      PMCID: PMC1415012     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

2.  Natural killer cells: definition of a cell type rather than a function.

Authors:  L L Lanier; J H Phillips; J Hackett; M Tutt; V Kumar
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

3.  Higher level expression of lymphocyte function-associated antigen-1 (LFA-1) on in vivo natural killer cells.

Authors:  T Nishimura; T Itoh
Journal:  Eur J Immunol       Date:  1988-12       Impact factor: 5.532

4.  Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies.

Authors:  N Rebaï; B Malissen
Journal:  Tissue Antigens       Date:  1983-08

5.  The detailed distribution of HLA-A, B, C antigens in normal human organs.

Authors:  A S Daar; S V Fuggle; J W Fabre; A Ting; P J Morris
Journal:  Transplantation       Date:  1984-09       Impact factor: 4.939

6.  "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype.

Authors:  R Kiessling; E Klein; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

7.  Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C.

Authors:  M Colonna; E G Brooks; M Falco; G B Ferrara; J L Strominger
Journal:  Science       Date:  1993-05-21       Impact factor: 47.728

8.  Susceptibility to natural killer cell-mediated cytolysis is independent of the level of target cell class I HLA expression.

Authors:  J M Leiden; B A Karpinski; L Gottschalk; J Kornbluth
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

Review 9.  Natural killer cells: their roles in defenses against disease.

Authors:  R B Herberman; J R Ortaldo
Journal:  Science       Date:  1981-10-02       Impact factor: 47.728

10.  Recognition of virus-infected cells by natural killer cell clones is controlled by polymorphic target cell elements.

Authors:  M S Malnati; P Lusso; E Ciccone; A Moretta; L Moretta; E O Long
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

View more
  7 in total

1.  Natural killer cell-produced IFN-γ and TNF-α induce target cell cytolysis through up-regulation of ICAM-1.

Authors:  Ruipeng Wang; Jessica J Jaw; Nicole C Stutzman; Zhongcheng Zou; Peter D Sun
Journal:  J Leukoc Biol       Date:  2011-11-01       Impact factor: 4.962

2.  Induction of transporter associated with antigen processing by interferon gamma confers endothelial cell cytoprotection against natural killer-mediated lysis.

Authors:  O Ayalon; E A Hughes; P Cresswell; J Lee; L O'Donnell; R Pardi; J R Bender
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

3.  QPY/RAH haplotypes of the GZMB gene are associated with natural killer cell cytotoxicity.

Authors:  Wataru Oboshi; Toru Watanabe; Keisuke Hayashi; Takehiro Nakamura; Nobuyasu Yukimasa
Journal:  Immunogenetics       Date:  2017-06-26       Impact factor: 2.846

4.  Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.

Authors:  Xiangling Wang; Astrid Ottosson; Chunyan Ji; Xiaoli Feng; Magnus Nordenskjöld; Jan-Inge Henter; Bengt Fadeel; Chengyun Zheng
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

5.  In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma.

Authors:  Wafaa S Khalaf; Mamta Garg; Yehia S Mohamed; Cordula M Stover; Michael J Browning
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

6.  Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation.

Authors:  Ting Lu; Rui Ma; Zhenlong Li; Anthony G Mansour; Kun-Yu Teng; Li Chen; Jianying Zhang; Tasha Barr; Michael A Caligiuri; Jianhua Yu
Journal:  Cancer Immunol Res       Date:  2021-07-29       Impact factor: 12.020

7.  Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.

Authors:  Henry Ji; Ying Yan; Beibei Ding; Wenzhong Guo; Mark Brunswick; Andreas Niethammer; Williams SooHoo; Robin Smith; Alexis Nahama; Yanliang Zhang
Journal:  Med Drug Discov       Date:  2020-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.